NEW YORK (GenomeWeb) – Cancer diagnostics developer Metamark Genetics announced today that it has signed a coverage deal for its urological cancer diagnostics with Blue Cross and Blue Shield of Texas, effective June 1.
The agreement covers all of BCBS insured members in Texas and gives them access to Metamark's array of urology specialized diagnostics.
Specific terms of the deal were not disclosed.
"Our continued momentum with payers across the US reflects the substantial value our comprehensive suite of products and services provides to patients, physicians, and insurers" said Metamark President and CEO Jerry Williamson in a statement. "We maintain our strong commitment to improve the care of patients with urologic cancer by expanding access to vital, decision-making information throughout the complete diagnostic and therapeutic care journey."
The Cambridge, Massachusetts-based company announced it had signed a similar deal with Anthem Blue Cross Blue Shield of Georgia in June, and with Highmark Blue Shield in Delaware, Pennsylvania, and West Virginia in April 2015.
Metamark offers the ProMark prognostic test for early-stage prostate cancer. The test is a proteomic classifier of biopsied tissue and predicts whether cancer can be managed without aggressive treatment or indicates that therapy may be appropriate.